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DETECTION OF ORAL TRANSGLUTAMINASES AND 
THEIR RELEVANCE IN CELIAC DISEASE 
ABSTRACT 
Celiac disease (CD) is an autoimmune disorder characterized by enteropathy caused by 
ingested gluten. Human transglutaminase 2 (TG 2) localized in the lamina propria of the 
small intestine modifies gluten by deamidating glutamine residues, which enhances 
gluten binding to T-cell receptors and downstream inflammatory immune responses. 
Many other human TGs and microbial transglutaminases (MTGs) share a similar 
catalytic activity with TG2. This study aimed to investigate the presence and activities of 
oral TGs from both human and microbial origins in whole saliva (WS) and dental plaque 
of healthy individuals. It also aimed to establish a method and positive control to detect 
MTG activity from oral bacteria. 
Unstimulated WS and dental plaque were collected from seven subjects with different 
ethnic backgrounds. The presence of TG2 in WS, concentrated WS supernatant and pellet 
was identified by Western blotting. TG activities in WS and dental plaque were 
determined by a fluorescent casein-monodansylcadaverine assay. Streptomyces 
mobaraensis TG was isolated and its activity was examined by a colorimetric 
hydroxamate assay. The sequence of S. mobaraensis TG was blasted against UniProt and 
HOMO databases to probe for oral bacteria that produce an MTG similar to S. 
mobaraensis TG. 
V 
The Western blots did not detect mammalian TG2 protein in WS, in concentrated WS 
supernatant or in WS pellet. Coomassie blue staining of the PVDF membrane verified 
efficient loading and transfer of proteins. A spike-and-recovery assay with TG2 
confirmed its detectability in WS. Like TG2, TG3 and TG5 appeared to be absent in 
saliva. Besides TG presence, TG activity was also examined. The highest TG activities 
were found in mixed WS ( 16.09 AU/min). Addition of a microbial TG blocker did not 
inhibit activities (18.16 AU/min), but addition of the mammalian TG blocker EDTA 
reduced activities to 12.12 AU/min. WS supernatant exhibited negligible activity (1.44 
AU/min) and the negative control (substrate only) exhibited no activity. While MTG 
blocker in saliva did not inhibit activity, transamination activities were detected in dental 
plaque, strongly suggesting that microbial TG is active in the oral cavity. The activity of 
MTG isolated from S. mobaraensis was confirmed. Blasting MTG from S. mobaraensis 
against the Uniprot database yielded matches with Streptom yces family members. The 
HOMD blast results yielded partial homologies with sulfatase (sulphatase)-modifying 
factor protein and serine/threonine kinase expressed by the oral Stenotrophomonas 
maltophilia with a score of 35.4 and a sequence homology of 25%. 
The data obtained suggest that TG2 is not detectable in saliva at the protein level. 
However, TG activity was detectable, and was primarily cell-associated. Both calcium-
dependent human TG and calcium-independent MTG from oral bacteria contribute to 
oral transamination activities. Oral TGs might play a hitherto unrecognized role in CD 
pathogenesi s, by modifying gluten prior to their transit to the small intestine. Further 
Vl 
studies should reveal the source and contributions of individual TGs to the observed TG 
activity in the oral cavity. 
Vll 
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1. INTRODUCTION 
1.1 CD and necessity for novel therapies 
Celiac disease (CD) is a multifactorial, autoimmune enteropathy that manifests in 
genetically susceptible individuals. It is triggered by gluten, a group of (glyco )proteins 
present in wheat and some other grains such as rye and barley. In CD patients, the 
abnormally increased permeability of the intestinal mucosa allows the passage of gluten 
peptides to the lamina propria where they activate both innate and adaptive immune 
responses and eventually cause tissue damage. Patients with undiagnosed CD can 
experience numerous complications, ranging from intestinal symptoms such as chronic 
diarrhea to more severe extra-intestinal symptoms such as anemia, osteoporosis, 
autoimmune disease, and gastrointestinal malignancies 1-3• Current! y, the estimated CD 
prevalence is about 1-2% in the Western population 4. This is probably still lower than the 
actual prevalence, considering that most CD patients are non-symptomatic and/or remain 
undiagnosed 5. 
At present, the only treatment for CD is a strict, lifelong gluten-free diet (GFD). 
Although most patients respond to the therapy when fully compliant, strict adherence to a 
GFD has significant socio-economic implications. Furthermore, the unavailability of 
gluten-free products in some geographic regions, and cross-contamination with gluten in 
food during processing pose additional challenges to GFD adherence. In addition, 
approximately 5% of patients are categorized as refractory celiac disease (RCD) patients, 
and develop uncontrolled duodenal inflammation despite strict adherence to a GFD 1• 
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Therefore, there is an urgent need for effective and affordable alternative treatments for 
CD as new insights into its pathogenesis are gained 6- 11• 
1.2 Human TG2 and its role in CD 
Transglutaminase 2 (TG2) is an ubiquitous enzyme consisting of 686 amino acids (78 
k.Da)12• It has the same catalytic activity to conduct transamidation and deamidation 
reactions as other members of human transglutaminase (TG) family, in spite of different 
localizations and regulatory mechanisms (Table 1). The catalytic mechanism of TG2 
resembles that of cysteine proteases. The active Cys site of the enzyme attacks y-
glutaminyl residues of proteins (glutamine donor) to form a thioester intermediate. A 
glutamine acceptor, such as an E-lysine residue or a small amine, reacts with the acylated 
enzyme and forms an isopeptidyl bond, crosslinking the proteins irreversibly. This 
process is called transamidation (Fig la, lb). Alternatively, when the glutamine acceptor 
is not available, the thioester intermediate reacts with water, resulting in the deamidation 
of a glutamine into glutamate (Fig lc) 13• The enzymatic activity of TG2 is calcium-
dependent 12• In the presence of calcium, the enzyme adopts an open conformation and 
becomes active. When calcium is absent , TG2 binds to GTP to form a closed and inactive 
conformation. 
Although human TG2 is ubiquitously expressed in various tissues, it is found in relatively 
high levels in the lamina propria of the duodenum. This presence is highly relevant to CD 
pathogenesis. The remarkably high substrate specificity of TG2 towards glutamine-rich 
gluten peptides 14- 16 results in the deamidation of gluten peptides into toxic peptides with 
2 
negatively charged glutamate residues. This strongly enhances the affinity of gluten for 
antigen presenting cells in the lamina propria and potentiates the subsequent activation of 
CD4+ T cells 17- 19• The interplay between gluten peptides and antigen presenting cells in 
the adaptive immune response is considered crucial in the early event of CD pathogenesis , 
and therefore, the keystone of CD development 20 (Fig. 2). 
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Table 1: Mammalian TG family members and their tissue distributions, biological 
functions, and regulatory mechanisms*. 
TG Nomenclature Tissue distribution Main biological Regulatory 
roles mechanisms 
TGl Keratinocyte Squamous epithelia, Differentiation of ca-+ 
TG keratinoc~tes keratinocytes 
TG2 Tissue TG Ubiquitous Stabilization and Ca2+ 
distribution remodeling of the Guanine 
extracellular nucleotides 
matrix; regulation Redox potential 
of cell death, 
differentiation 
and aeoetosis 
Ca2+ TG3 Epidermal TG Epidermis, hair Differentiation of 
follicle, brain keratinocytes Guanine 
nucleotides 
TG4 Prostate TG Prostate gland, Seminal vesicle Unknown 
erostatic fluids coagulation 
TG5 TGX Female reproductive Epidermal Unknown 
tissues, foreskin differentiation 
keratinocytes, 
skeletal muscle 
TG6 TGY Lungs, brain, testis Unknown Unknown 
TG7 TGZ Lungs, testis Unknown Unknown 
FXIIIA Factor XIII A Synovial fluid, eye, Wound healing Ca2+ 
heart,bone,dermis and fibrin clotting 
Band Erythrocyte Bone marrow, Stabilization of Unknown 
4.2 membrane spleen erythrocyte 
protein band membrane 
4.2 
* Adapted from "Biological Functionalities of Transglutaminase 2 and the Possibility of 
Its Compensation by Other Members of the Transglutaminase Family," The Scientific 
World Journal, vol. 2014, no. 31, pp. 1-13, 2014. 
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Figure 1. Calcium-dependent enzymatic act1v1ty of TG2. In the presence of a 
glutamine acceptor, such as a small amine (A) or an £-lysine residue (B), TG2 
mediates the transamidation reaction and crosslinks glutamine donor protein and 
glutamine acceptor protein with an isopeptidyl bond. In the absence of a glutamine 
acceptor , TG2 mediates the deamidation reaction (C) , in which the glutamine donor 
reacts with water and forms a negatively charged glutamate residue. 
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Figure 2. TG2 in the pathogenesis of CD. Adapted from "Transglutaminases in 
inflammation and fibrosis of the gastrointestinal tract and the liver," Digestive and Liver 
Disease, vol. 41, no. 8, pp. 541-550, Aug. 2009. 
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1.3 Human TG2 inhibitors for CD therapy 
Based on the role of TG2 in the formation of toxic gluten peptides and enhancing 
immune response in CD pathogenesis, TG2 inhibitors have emerged as a possible 
treatment for CD patients. Both reversible (competitive inhibitor and non-competitive 
inhibitor) and irreversible TG2 inhibitors are being explored. 
The competitive inhibitors, which contain a terminal primary amine in their structures, 
compete with natural amines to crosslink with the natural glutamine donor21• The non-
competitive inhibitor, such as guanosine triphosphate (GTP) and guanosine diphosphate 
(GDP), blocks TG2 activity by preventing substrate from binding to the enzyme active 
site. Irreversible inhibitors inactivate TG2 by covalently modifying the enzyme and 
preventing substrate binding 22-24 . The effect of TG2 inhibitors in alleviating gluten-
induced immune response has been shown in several CD research models, including 
intestinal epithelial cells23 , intestinal T cells from CD patients 21, and intestinal biopsy 
cultures from CD patients 21•24 . 
The drawback of using TG2 inhibitors lies in the lack of inhibitor specificity. E.g. other 
TG family members such as TG3 and TG5 also bind guanine nucleotides. Furthermore, 
the ubiquitous expression pattern of TG2 necessitates tissue specificity of inhibitor 
actions to avoid serious side effects. 
1.4 MTG and its potential therapeutic role in CD 
In addition to TGs in mammalian species, TGs have also been identified in prokaryotic 
species, among which the microbial transglutaminase (MTG) from S. mobaraensis is the 
most studied 25-30 . Since its discovery in 1980s, MTG has been of great industrial 
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importance and has been widely used in the food processing industry to change food 
texture by crosslinking proteins. It is active over a wide range of temperatures and stable 
between pH 5.0 and 9.031• Unlike human TGs, MTG catalyzes protein crosslink 
efficiently without the need for the presence of calcium. It displays broad acyl-acceptor 
substrate specificity 29 and gluten peptides are among one of its most well bound 
substrates. 
MTG derived from S. mobaraensis has been used to pretreat gluten peptides and 
crosslink glutamine residues that would otherwise act as deamidation substrates for 
TG2 6'32'33 . The pretreatment with S. mobaraensis-derived MTG detoxifies gluten peptides 
and is regarded as a promising treatment alternative to a GFD. However , no study has 
investigated whether bacteria in the oral cavity produce TG. 
1.5 TGs in the oral cavity 
One overlooked source of TG is the oral cavity. The oral cavity is the portal via which 
immunotoxic gluten peptides reach the gastrointestinal system. It has been shown that TG 
is present in human saliva and its activity contributes to the formation of the salivary-
mucosal pellicle by mediating the cross links between salivary proteins and other 
proteins 34-36 . Human saliva contains cells and cellular products from both mammalian and 
bacterial origins. While some studies, using specific antibodies against TG 1, 2, 3, 4, have 
provided preliminary evidence that mammalian TGs are detectable in human saliva37, 
additional potential sources of oral TG have not yet been explored. Dental plaque in the 
oral cavity provides an optimal niche for a pool of various species of bacteria. No study 
8 
has investigated the presence of MTG from oral bacteria and its potential role in CD 
pathogenesis. 
1.6 Potential role of oral TGs in CD 
The oral mucosa is regarded as an immunologically active site in CD. When challenged 
with immunotoxic gluten peptides, there is some correlation between inflammatory 
responses in the oral mucosa and intestinal mucosa in terms of autoantibody production 
and T cell activation 38-40. The possibility that catalytic modifications of gluten peptides 
by transamidation and/or deamidation reactions may start already in the oral cavity by 
human and/or microbial oral TGs is of great interest. A thorough characterization of 
human oral TGs will be critical in determining if very early events in CD pathogenesis 
might already occur at the entry of gastrointestinal system, the oral cavity. This study 
may also reveal potential therapeutic strategies for gluten detoxification through cross-
linking activity by human or microbial TG, in analogy to strategies proposed for S. 
mobaraensis MTG. 
2. AIM OF THE STUDY 
In the present study, we investigated the presence and activities of oral TGs in WS and 
dental plaque of healthy individuals. We also established a method to detect MTG 
activity from S. mobaraensis as a positive control for future oral MTG activity 
scree nm gs. 
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3. MATERIALS AND METHODS 
3.1 Sample collection and preparation 
3.1.1 Collection and preparation of human WS samples 
Unstimulated WS was collected with a standardized collection protocol. Seven healthy 
subjects from different ethnic backgrounds rinsed their mouths to remove any potential 
residual food or debris. Subjects were then asked to expectorate 5 ml of resting WS into a 
50 ml conical tube on ice. A 1 ml WS sample aliquot from each subject was centrifuged 
at 5,000 x g for 10 min. The supernatant fraction derived from 1 ml unstimulated WS of 
each subject was dried and dissolved in 20 µl distilled water to be further examined by 
Western blots. The pellet samples were washed twice with 500 µl saliva ion buffer and 
kept at -20°C. 
3.1.2 Collection and preparation of human dental plaque samples 
The participating healthy subjects were instructed to avoid flossing for 3 days to facilitate 
the formation of dental plaque. After mouth rinsing, dental plaque was collected by the 
donor from the tooth surfaces and inter-proximal spaces using an explorer (The Doctor's , 
Tarrytown, NY). The samples were then homogenized in a calcium-free buffer (80 mM 
Tris-HCl, pH 7.5) and standardized to an OD62o of 1.0. 
3.2 Western blotting 
10 
Proteins were separated by electrophoresis on a 4-12% NuPAGE Bis-Tris mini gel and 
blotted onto a PVDF membrane. The membrane was then blocked with 5% (w/v) non-fat 
dried milk and 0.1 % (w/v) Tween 20 in TBS, followed by incubation with anti-TG2 
antibody (A003 Zedira) at a 1 :500 dilution for 1 hour at room temperature. The 
secondary antibody (HRPO-conjugated) was used at a 1: 1,000 dilution for 1 hour at room 
temperature and binding was visualized with a chemiluminescent reagent kit 
(SuperSignal® West Pico Chemiluminescent Substrate, Thermo Scientific 34077). 
Recombinant human TG2 (rhTG2; T002 Zedira) at 0.5 µg was used as positive control. 
After film exposure , the PVDF membrane was stained with 0.25% Coomassie blue for 30 
min, followed by destaining in 5% methanol, 7.5% acetic acid , 87.5% deionized water 
until protein bands were observed with a clear background. 
3.3 Isolation of MTG from S. mobaraensis 
The cultivation of S. mobaraensis and production of S. mobaraensis-derived MTG 
generally followed a published MgC}i-modified protocol 27• In brief, 2 ml ISP-medium 
(Difeo ISP-medium, BD) was added to rehydrate the commercially obtained S. 
mobaraensis pellet (ATCC 29032). To obtain spore cultures on agar, two drops of the 
well-mixed suspension were spread onto malt extract agar plates (Hardy Diagnostics) and 
cultured at 26°C. To generate glycerol stocks , the bacteria were aseptically transferred to 
a 1 ml solution containing 200 µl sterile glycerol and 800 µl ISP medium, and vials were 
stored at -80°C. The rest of the rehydrated suspension was added to 100 ml ISP medium 
in a 250 ml flask while shaking at 26°C, 180 rpm. After cultivation for 3 days, 2 ml 
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culture solution was added to 100 ml MgCh-supplemented culture medium in a 250 ml 
flask while shaking at 180 rpm at 26°C for 4 days. The MgCh-supplemented culture 
medium was composed of 3% polypeptone, 1 % soluble starch, 1 % fructose, 0.2% 
K2HPO4, 0.1 % MgSO4· 7H2O, and 2% MgCh-6H 2O. The pH was adjusted to 7 .0 before 
autoclaving. The resulting culture was centrifuged at 20,000 rpm (47,808 g) for 20 min. 
A 10 kDa centrifugal filter was used to concentrate the MTG in the supernatant, which 
has a reported molecular weight of about 39 kDa27. The resulting "sticky" concentrated 
supernatant was diluted in 2 ml MTG buffer (80 mM Tris-HCI buffer, pH=7.5) to achieve 
a 50-fold concentrated MTG. All samples were aliquoted and stored at -80°C. 
3.4 TG activity assay 
3.4.1 Fluorescent casein-monodansylcadaverine assay 
Monodansylcadaverine (MDC, Sigma), containing a primary amine, was used as a amine 
donor and casein was used as a glutamine donor. The crosslinking of MDC and casein 
enhanced fluorescence of the dansyl group, which was used as an indicator of TG activity 
(Fig. 3). To detect human TG activity, 85 µl WS sample was incubated with 30 µM 
monodansylcadaverine and 0.02% (w/v) casein in a total volume of 100 µl calcium-
containing buffer (O. lM Tris-HCI, 0.15M NaCl, 5mM CaCh, pH 7 .5). To detect bacterial 
TG activity, a dental plaque suspension in a calcium-free buffer (80 mM Tris-HCI, pH 
7 .5) was standardized to an OD620 of 1.0. An 85 µl aliquot of the standardized sample 
was incubated with 30 µM monodansylcadaverine and 0.02% (w/v) casein in a total 
12 
volume of 100 µl. Excitation was set to 360 nm and the increase in fluorescence intensity 
was measured at 535 nm using a fluorescence spectrophotometer (Genios, Tecan, 
Mannedorf, Switzerland). 
~ TG2/Ca 2+ 
+ 
NH2~ 
:s:· 
Figure 3. Chemical reactions in the casein-monodansylcadaverine assay. 
Monodansylcadaverine (MDC) was used as a glutamine acceptor and casein was used as 
a glutamine donor. TG2 mediates the crosslinking of MDC and casein and enhances 
fluorescence of the dansyl group, which was used as an indicator of TG activity. 
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3.4.2 Colorimetric hydroxamate assay 
CBZ-Gln-Gly was used as a glutamine donor and hydroxylamine was used as a 
glutamine acceptor. In the presence of TG, CBZ-Gln-Gly is crosslinked with 
hydroxylamine and develops a colored complex with iron. The color change can be 
measured and used to quantitate TG activity (Fig. 4). A 30 µl aliquot of S. mobaraensis-
derived MTG concentrate was incubated at 37°C with 120 µl substrate mixture (37.5 mM 
CBZ-Gln-Gly, 125 mM hydroxylamine, and 12.5 mM glutathione in 200 mM citrate 
buffer, pH 6.0) for 10, 25, 40, and 60 min. Then 40 µl tracker solution (5% FeC13 in 15% 
TCA) was added for 10 min of incubation at 37°C. The absorbance at 492 nm was 
measured to determine the enzyme activity. 
CBZ-Gln-Gly MTG CBZt:~ 
~o 
+ N~OH + NH3 
HiN HOHN 
CBZi:: CBZ-Glu-Gty Fe3 /H• 
~c( 0 
HOHN HON \, Fe 
3 
Figure 4. Chemical reactions in the colorimetric hydroxamate assay. CBZ-Gln-Gly was 
used as a glutamine donor and hydroxylamine was used as a glutamine acceptor. In the 
presence of TG, CBZ-Gln-Gly is crosslinked with hydroxylamine and three cross-linked 
molecules coordinate one iron ion to develop a colored complex. The color change can be 
measured and used to detect TG activity. 
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3.5 Data mining for oral microbial TG with a bioinf ormatics approach 
The full sequence of S. mobaraensis MTG (P81453, UniProt) was used for blasting 
against sequences m the UniProt protein database available at 
http://www.uniprot.org/blast. The parameters were set as follows: Target database = 
"UniProtKB", E-Threshold = "10", Matrix = "Auto", Filtering = "None", Gapped = 
"yes", Hits = "250". The results were ordered by "Score" and limited within the 
Taxonomy of "Bacteria". The full sequence of S. mobaraensis MTG (P81453, UniProt) 
was also used for blasting against sequences in the HOMD available at www.homd.org. 
The parameters were set as follows: Filter= "Low complexity", Expect= "10", Matrix= 
"BLOSUM62", Alignment view= "Pairwise", Descriptions= "100", Alignments= "50", 
Color schema= "No color schema". 
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4. RESULTS 
4.1 Detection of TG2 in human WS 
4.1.1 Detection of TG2 in fresh WS 
WS samples collected from seven subjects were loaded on a 4-12% NuPAGE Bis-Tris 
mini gel to examine the expression of TG2. As shown in Figure 5a, no band was present 
in any of the WS samples analyzed (lane 1-7) while the TG2 positive control (0.5 µg 
human recombinant TG2, rhTG2; lane 8) showed a band at 78 kDa as expected. 
To confirm that the absence of TG2 in the experimental samples was not caused by 
inefficient protein transfer onto the PVDF membrane, the membrane was stained with 
Coomassie blue after x-ray film exposure to examine the amount of proteins on the 
membrane (Fig. 5b ). All sample lanes (lane 1-7) showed properly loaded and transferred 
WS proteins with various molecular weights. The positive control was shown as a thin 
but discernable band with the expected molecular weight of 78 kDa. The Coomassie blue 
staining of salivary proteins was much stronger than the positive control. This result, 
combined with the Western blot findings, suggested that TG2 was expressed at an 
undetectable level in fresh WS, if expressed at all. 
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Figure 5: Assessment of TG2 in WS. A 20 µl aliquot of non-stimulated WS from seven 
subjects (WS l-WS7) was loaded in lanes 1-7. A 0.5 µg human recombinant TG2 aliquot 
was loaded in lane 8. A, blots incubated with anti-TG2 antibody (Zedira A003). B , blot s 
stained with 0.25% Coomassie blue. 
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4.1.2 Detection of TG2 in the supernatant fraction of WS 
The undetectable TG2 expression could also result from a low concentration of TG2 in 
WS. To further investigate the possible expression of TG2, we centrifuged WS samples 
and separated WS into a supernatant fraction and a pellet fraction. The supernatant was 
then concentrated 50 x and analyzed. As shown in Figure 6a, no band was present in any 
of the concentrated supernatant samples (lanel- 7) while the band of the TG2 positive 
control (lane 8) was present at 78 kDa as expected. 
To confirm again that the absence of TG2 bands was not caused by inefficient protein 
transfer, the PVDF membrane was stained with Coomassie blue after film exposure (Fig. 
6b ). All sample lanes showed properly loaded and transferred WS proteins with various 
molecular weights. This result, combined with the previous Wes tern blot findings, 
suggested that TG2 was present at negligible levels in WS supernatant. 
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Figure 6. Assessment of TG2 in WS supernatant. The supern atant fraction of 1 ml WS of 
seven subject s (Sl-S7 ) was loaded in lanes 1-7. A 0.5 µg human recombin ant TG2 
aliquot was loaded in lane 8. A, blot s incubated with anti-TG 2 antibody. B, blots stained 
with 0.25 % Coom assie blue. 
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4.1.3 Detection of TG2 in the pellet fraction of WS 
To investigate if TG protein could be detected in the cellular fraction of WS, the pellet 
fraction derived from 1 ml non-stimulated WS of each subject was washed with saliva 
ion buffer and loaded. As shown in Figure 7a, no band was present in any of the pellet 
samples (lane 1-7) while the band of the TG2 positive control (lane 8) was present at 78 
kDa as expected. 
The proteins were efficiently transferred to the PVDF membrane (Fig. 7b ). The bands 
showed a smear-like pattern compared to the well-separated bands in the supernatant 
samples, which is likely due to unresolved particulate matter in the loaded cell 
suspensions. This result, combined with previous Western blot findings, indicates that 
TG2 was neither detectable in the supernatant nor in the pellet fraction of WS. 
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Figure 7. Assessment of TG2 in WS pellet. The pellet of 1 ml non-stimulated WS of 
seven subjects (Pl -P7) was loaded in lanes 1-7. A 0.5 µg human recombinant TG2 
aliquot was loaded in lane 8. A, blots incubated with anti-TG2 antibody (Zedira A003). 
B, blots stained with 0.25% Coomassie blue. 
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4.1.4 Validation of TG2 detection in WS with a spike-and-recovery method 
The absence of TG2 detection in the WS-derived samples could potentially be caused by 
components masking TG2 detection in the WS context. To examine this possibility, a 
known amount of rhTG2 was added to pooled WS of all seven subjects, and the rhTG2 
protein levels were compared to the same amount of rhTG2 added to buffer, examined by 
Wes tern blotting. 
As shown in Figure 8, added rhTG2 protein was detectable in WS and in buffer, 
excluding masking effects by WS components. As in the previous experiments, the 
unspiked WS samples showed no evidence for the presence of TG2. Therefore, 
undetectable TG2 in WS was due to bona fide negligible levels rather than to an 
experimental artifact. 
Similar experiments were carried out with antibodies directed at human TG3 and TG5. 
The results indicated that these TGs were also undetectable in WS, WS supernatant, and 
WS pellet (data not shown). The results could not be interpreted unequivocally due to the 
unreliability of the recombinant TG3 and TG5 controls. However, their absence in saliva 
is consistent with the observations made with TG2. 
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Figure 8. Spike-and-recovery assay of rhTG2 added to WS. Lane 1, A pooled 20 µI WS 
sample aliquot; lane 2, WS spiked with rhTG2; lane 3, rhTG2 in buffer. Blots were 
incubated with anti-TG2 antibody. 
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4.2 TG activity in the human oral cavity 
4.2.1 TG activity in WS 
A monodansylcadaverine assay was used to determine TG activity in WS. The assay 
measures activities from TG enzymes derived from both human and bacterial origins. A 
calcium-containing buffer was used for testing the calcium-dependent crosslinking 
reaction conducted by human TG. EDTA, a chelating agent of calcium ions, was used to 
inhibit the calcium-dependent reactions conducted by human TGs and to reveal the 
calcium-independent activity of TG from bacterial sources. MTG blocker is an efficient 
blocker of S. mobaraensis MTG, and was used as a tentative inhibitor of all oral 
microbial TG. Guinea pig TG was used as a positive control. 
The TG activity curves in the "whole saliva" group, "whole saliva + MTG blocker" 
group, and "guinea pig TG" group all showed linear increases in fluorescence over time 
(examined time span 0-60 min). TG activity in the "whole saliva+ EDTA" group reached 
a plateau at 40 min, suggesting the EDTA might be an effective inhibitor, but that it 
required some time to effectively inhibit enzyme activity. Of note, the WS samples were 
not preincubated with EDT A prior to the addition of the substrate. Guinea pig TG 
showed slightly different kinetics of activity than the WS samples, indicated by the 
tendency that yielded a sigmoidal shaped curve in the early phase of incubation. The 
"WS supernatant group" readings were similar to the substrate only group, demonstrating 
very low activities. The steep increases in the fluorescent signals in the WS supernatant 
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and substrate only samples between 0-6 min were attributed to an experimental artifact 
and therefore this time span was excluded from the rate calculations. 
The rates of product formation were determined from the slopes of the fluorescence 
increase over time during the 6-40 min time interval. The calculated rates for the "whole 
saliva" group and "whole saliva+ MTG blocker" group were 16.09 AU/min and 18.16 
AU/min respectively, showing little effect of the addition of the MTG inhibitor on WS 
activity. Addition of EDTA reduced the overall TG activity in WS significantly tol2.12 
AU/min. The supernatant fraction of WS had a very low activity ( 1.44 AU/min) and as 
expected no activities were observed in the negative control (-2.25 AU/min). Guinea pig 
TG, used as the as the positive control, demonstrated rates of 39.33 AU/min during the 
linear part of the reaction curve (12-20 min). 
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Figure 9. TG activity measurement in WS. Monodansykadaverine was used as 
glutamine-acceptor substrate and its crosslinking to added casein as the glutamine-donor 
was used to monitor the enzymatic activity of TG. A 85 µl aliquot of a pooled WS 
sample was incubated with 30 µM monodansylcadaverine and 0.02% (w/v) casein in a 
total volume of 100 µl calcium-containing buffer (0.1 M Tris-HCl, 0.15M NaCl, 5mM 
CaC12, pH 7 .5). Excitation was set to 360 nm and the increase in fluorescence intensity 
was measured at 535 nm with a fluorescence spectrophotometer. The data shown are 
results of a single reading. 
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4.2.2 Microbial TG activity in dental plaque 
While MTG inhibitor did not inhibit crosslinking activities in WS, microbial-derived TG 
activities were further investigated in a suspension of dental plaque. The MDC 
experiment was conducted in calcium-free buffer, to exclude contributions by human 
TGs. In the absence of a positive MTG control, guinea pig TG was used, which was 
examined in calcium containing buffer. 
As shown in Figure 10, the highest TG activity was found in the "dental plaque + 
substrate" group. The "guinea pig TG + substrate" group showed again a sigmoidal 
shaped curve in activity over time. The negative control, the "substrate only" group, 
showed little TG activity throughout the entire time span of the experiment (0-60 min). 
The results provide strong evidence that dental plaque is a source of MTG, although 
validation with appropriate inhibitors should be conducted for further confirmation. 
Microbial TG may contribute to transamination and deamidation reactions in the oral 
cavity. 
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Figure 10. MTG activity detection in dental plaque. Monodansylcadaverine was used as 
glutamine-acceptor substrate and its cross-linking to casein was used to indicate the 
enzymatic activity of TG. Dental plaque sample in a calcium-free buffer (80mM Tris-
HCl, pH 7 .5) was standardized to OD 1.0. A 85 µl aliquot of the standardized sample was 
incubated with 30 µM monodansylcadaverine and 0.02% (w/v) casein in a total volume 
of 100 µl. Excitation was set to 360 nm and the increase in fluorescence intensity 
measured at 535 nm with a fluorescence spectrophotometer. The data shown are average 
values of triplicates. The error bar represents the standard error of the mean (SEM). 
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4.3 Isolation of S. mobaraensis MTG 
The promising results of MTG activity in dental plaque prompted us to make further 
efforts to develop a suitable screening assay to discover oral microbes producing TG. For 
such screenings, a positive control of microbial origin was needed. S. mobaraensis has 
been well established to produce MTG. In this study, we concentrated the microbial TG 
produced by this microorganism. 
A colorimetric hydroxamate assay was conducted to detect S. mobaraensis MTG activity. 
In contrast to the MDC-casein assay, the hydroxamate assay allows for a more direct 
visualization of activity by a macroscopic color change. This method would greatly 
increase the efficiency in screening for potential oral bacteria capable of producing TG in 
future studies. 
4.3.1 Production of concentrated MTG from S. mobaraensis 
S. mobaraensis was cultured on malt agar. After cultivation at 26°C for 2 days, S. 
mobaraensis formed colonies ( 100~ 150 colonies/plate) on malt extract agar plates with 
diameters between 1-8 mm. On day 3, colonies enlarged with diameters between 3-10 
mm. The colonies then became covered with a fuzzy white aerial mycelium and merged 
together (Fig. 11 ). 
The S. mobaraensis cultured in ISP medium at 26°C formed small sphere-shaped white 
solid aggregates on day l, which grew into larger aggregates with regular sphere shape 
and irregular shapes on day 2 and day 3 (Fig. 12). The medium remained clear and no 
contamination was observed throughout the duration of culture. 
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Figure 11. Visualization of S. mobaraensis growing on malt extract agar plates. The S. 
mobaraensis formed colonies on day 2 (A, B), and grew into larger colonies on day 3 (C, 
D) on malt extract agar plates. No contamination was observed throughout the duration of 
the culture. 
A B C 
Figure 12. Visualization of S. mobaraensis growing in medium. S. mobaraensis formed 
aggregates on day 1 (A), and grew into larger aggregate on day 2 (B) and day 3 (C) in 
the medium. No contamination was observed throughout the duration of the culture. 
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4.3.2 Detection of MTG activity derived from S. mobaraensis 
S. mobaraensis MTG is released into the medium. Concentrated medium was evaluated 
for activity using the colorimetric hydroxamate assay. To eliminate the effect of yellow-
colored concentrated MTG on absorbance results in the negative control group, MTG 
was added right before the absorbance reading. 
As shown in Figure 13, the MTG activity was significantly higher in the "MTG-induced 
crosslink" group than that in "negative control" group. The "MTG-induced crosslink" 
group showed a linear increase during the entire reaction period (0-60 min), while the 
"negative control " group remained at a baseline activity. This indicates that the sample 
contained MTG activity, which could be further confirmed with MTG inhibitor. 
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Figure 13. Colorimetric hydroxamate assay to test the activity of concentrated MTG 
produced by S. mobaraensis. An aliquot of 30 µl of concentrated S. mobaraensis-derived 
MTG was incubated at 37°C with 120 µl substrate mixture (37.5 mM CBZ-Gln-Gly, 125 
mM hydroxylamine, and 12.5 mM glutathione in 200 mM citrate buffer, pH=6.0) for 10, 
25, 40, and 60 min. Then 40 µl tracker solution (5% FeCb in 15% TCA) was added for 
10 min of incubation at 37°C. The absorbance at 492 nm was measured to determine 
enzyme activity. The negative control contained the same components except that the 
concentrated MTG was added right before the absorbance reading instead of at the 
beginning of the assay. The data shown are average values of triplicates. The error bar 
represents the standard error of the mean (SEM). 
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4.4 Data mining for oral microbial TG with a bioinf ormatics approach 
To identify MTG-producing oral bacteria that may be responsible for the MTG activity 
detected in the dental plaque samples, the sequence of S. mobaraensis MTG was blasted 
in UniProt (Fig. 14). The results were limited in the category of "Bacteria" and were 
sorted by score. In total, 34 matches were found. As expected, most results with the 
highest scores were matches to proteins expressed by the Streptomyces family, including: 
S. mobaraensis, S. roseoverticilla, S. cinnamoneus , S. platensis, S. hygroscopicus , S. 
paucisporogenes , S. netropsis , S. fradiae, S. caniferus , and S. auratus. All of them 
contained the catalytic triad of S. mobaraensis-derived MTG: Cys140, Asp33 l, His350 
(Fig. 15). Matches with proteins from some other bacterial species were found as well. 
For example, transglutaminase from Saccharomonospora viridis was ranked with a 100% 
sequence homology. In addition, matches to proteins from a few other species were found 
with lower sequence homology: Kutzneria albida (27 .4% ), Planctomyces limnophilus 
(31.1 % ), Edwardsiella tarda (34.9% ), Edwardsiella piscicida (34.9% ), Acidovorax 
(30.8% ), Pseudoalteromonas rubra (24.9% ), Rhizabium grahamii (26.0% ), 
Mycobacterium kansasii (32.2% ), and Defluviimonas (33.3% ). However, none of the 34 
identified bacteria was listed in HOMD as a common inhabitant in oral cavity. We also 
blasted the sequence of S. mobaraensis MTG against the oral microbial genome ORFs 
available at www.homd.org. We found matches with proteins expressed by 3 different 
strains of Stenotrophomona s maltophilia, with scores of 35.4 and sequence homology of 
25%. They were sulfata se-modifying factor protein produced by Stenotrophomona s 
maltophili a AU l 2-09 (gil460867544lgblEMI49235. l I), serine/threonine kinase produced 
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by Stenotrophomonas maltophilia D457 (gil384078842lemblCCH 13435.1 I), and 
sulphatase-modifying factor protein produced by Stenotrophomonas maltophilia JV3 
(gil343779544lgblAEM52097 .11). In summary, based on the limited number of sequenced 
oral species to date (4,329,907 sequences), Stenotrophomonas maltophilia was the only 
oral microbe identified as expressing proteins with some level of similarity to S. 
mobaraensis-derived TG. The actual deamidating/transamidating activities of these 
proteins are questionable given the low sequence overlap, and would need to be validated 
in pure cultures. 
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Figure 14. The protein sequence of S. mobaraensis-derived MTG. The three amino acids 
composing the catalytic triad of MTG are indicated with arrows: C140, D331 , H350. 
A B 
Figure 15. Structure of S. mobaraensis-derived MTG (PDB ID: 3 IU0). A, overall 
structure of MTG. The three amino acids composing the catalytic triad of MTG (Cys140, 
Asp331, and His350) are enclosed by the yellow circle; B, structure around the active 
ite of MTG. The active site of MTG are repre ented by the red wire model. Figure 
were adapted from "Crystal Structure of Microbial Transglutaminase from 
Streptoverticillium mobaraense," Journal of Biological Chemistry, vol. 277, no. 46 , pp. 
44252--44260,Nov . 2002 . 
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Figure 16. Results of blasting the S. mobaraensis MTG sequence in UniProt. 
36 
100.0 % 
100 .0% 
99 .0% 
100 .0% 
88 .8% 
88 .5% 
100 .0% 
94 .2% 
93 .7% 
78.6% 
75 .7% 
75.5 % 
92.5 % 
74 .2% 
74 .0% 
73 .8% 
74.0% 
74 .0% 
73 .9% 
74 .2% 
73.6% 
75 .5% 
68 .4% 
74 .8% 
79.6% 
27.4 % 
31.1 % 
34 .9% 
34.9% 
30 .8% 
24.9% 
26 .0% 
32.2% 
33.3 % 
Score E 
Sequences producing sign ~ ficant a · gnments: (bis) Va ue 
gi l 46 0 8675 4 j gb EMI49235. I su a ase - modifying factor pro ein [ .. . 
g il 38 0 88 2 l emb !CCB 3435. I serine / th reonine Kinas ( Stenotroph .. . 
gi l 343 7 7 9 5 4 1gb AEMS2097. I Su pha ·tase - modifying factor protein ... 
>gi l 460867544 l gb l BMI49235.l l sulfatase modify ' ng £actor prot ein 
( S e no t rophomonas mal t op hili a AU12 - 09 ) 
Lengt h • 630 
Score • 35.4 b ' ts (80 ) , Expect • 4 .4 
Iden i ies • 3 / 124 (2 5 ), Pos i i ves • 52 / 12 ( 4 ), Gaps • 7 / 124 (S ) 
Query: 28 RSSSADKRXYGDPDAFR.PAPGTGLVDMSRDRNIPRSPTSPCEGFVNFDYGWFGAQTEADA 343 
R S CD A P PG4C S D • S F + GW+G A 
Sbjct: 492 RAGSSGRYPWGD-- AGTPPPGSGNFTGS!l:D-- VSPSCRBWB"AFIG YGDGWWGPAPVASF 54 7 
Query: 344 DKTVWTHGNBYBAPNGSLGAMBVYESKFRNW- SEGYSDFDRGAYVITFI PKSWNTAPOKV 4 02 
G B A N S -+-R S G F G W AP 
Sbjct: 548 QANAF--GLBDM.AGNLSBWVADCWBASYRRAPSDGVAWPNPGCRSRVIRGGNWANAPEO 605 
Query: 403 KQGW 406 
w 
Sb j ct: 606 RAAW 609 
>gi l 384 078 842 l emb j CCR13 435.l l serine / hreonine ki n ase 
( St eno rophomonas mal op hi i a D45 ) 
Leng th • 628 
Score • 35.4 b it s ( 80 ) , Expect • 4.4 
Ident i ies • 32 / 124 (25%), Posi ives • 5 / 124 (4 %) , Gaps • 7 / 12 ( 5%) 
4. 4 
4.4 
4 . 4 
Query: 284 RSSSADKRKYCDPDAFRPAPGTGLVDMSRORNIPRSPTSPGEGFVNFOYGWFGAQTEADA 343 
R S GD A PPG G SD S FV GW G A 
Sb ' ct: 49 0 RAGSSGRYPWGD-- AGTPPPGAGNFTGSKD-- VSPSCRHWBNAFVGYGDGWWCPAPVASF 545 
Query: 34 DKTVWTHGNBYBAPNGSLGA.\ffiVYESKFRNW- SEGYSDFDRGAYVITFIPKSWN APDKV 402 
G 8 A N S -+-R S• G + F G W AP 
Sb j c t : 546 QANAF- - GLBDMAG SEWVADCWHASYR.~SDGVAWFNPGCRSRVIRGGNWANAPEQT 603 
Query: 403 KQCW 406 
.. w 
Sb j ct: 604 RAAW 60 7 
>gi l J 3779544 j gb lABMS2097. I Sulphatase - mod if y i ng factor pro tein 
{S enotrophomonas mal t op hi ia JV3J 
Lengt. • 630 
Score • 35 . 4 b it s (80) , Expect • .4 
Identi t ies • 3 / 124 ( 25% ) , Pos iti ves • 52 / 12 ( 4 %) , Gaps • 7 / 12 ( 5 ) 
Query: 28 RSSSADKRKYGDPDAFRPAPGTGLVDMSRDRNIPRSPTSPGEGFVNFDYGWFGAQTEADA 343 
R S GD A PPG G SD S F + GW+G A 
sb ·ct: 492 RAGSSGRYPWGD-- AGTPPPGSGNFTGSKD-- VSPSGRBWBNAF GYGDGWWGPAPVASP 54 
Query: 34 DKTVWTHGNBYBAP GSLGAMHVYESKFRNW- SEGYSDPDRGAYVITFIPKSWN APDKV 402 
CB ANS R SG F G W AP 
Sb j ct: 54 8 QANAF-- GLBDHAGNLSEWVADCWRASYRRAPSDGVAWPNPGCRSRVIRGGiWANAPEQ 6 05 
Query: 403 KQGW 4 0 6 
w 
Sb j c . 606 RAAW 609 
Figure 17. Results of blasting S. mobaraensis MTG sequen ce in HOMD. 
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5. DISCUSSION 
5.1 Detection of TG2 in human WS 
TG2 was first identified as the autoantigen of CD in 199741• It was found to form 
complexes with gliadin through transamidation, which initiated the immune response 
directed against TG2 and gliadin , and resulting in tissue damage in CD. Subsequent 
studies have shown that the TG2-mediated deamidation of gliadin peptides led to an 
increased binding of gliadin to antigen presenting cells 17- 19• In addition to conducting 
deamidation of gliadin and thereby enhancing immune responses , TG2 also represents the 
target for CD-specific antibodies that are likely to play a role in CD pathogenesis. 
Therefore, a thorough characterization of TG2 (and any other enzymes that can conduct 
TG2-like reactions) in the oral cavity, the entrance of all gliadin peptides, is of significant 
importance to advance our understanding and treatment of CD. 
In this study , we examined TGs in WS instead of glandular secretion in order to include 
salivary proteins from cells present in the oral cavity. The compositions of WS include 
secretions from human salivary glands and oral bacteria, gingival crevicular fluid (GCF), 
oral mucosa! epithelial cells, and oral bacteria cells. After centrifuging WS, the soluble 
components remain in the supernatant while the cellular components form the pellet 
fraction. 
Proteins in WS were separated by electrophoresis and blotted onto PVDF membranes. 
After staining WS proteins on the membranes with Coomassie Brilliant Blue, several 
major components of saliva could be observed with molecular weights similar to 
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amylase, agglutinin, lysozyme, lactoferrin, mucins , immunoglobulins, cystatins, proline-
rich proteins and histatins. Immunoblotting with an anti-TG2 antibody showed that TG2 
was not present in fresh WS, the supernatant fraction of WS, or the pellet fraction of WS. 
The spike-and-recovery assay showed rhTG2 could be detected in a WS sample and that 
its detection was not obscured by large glycoproteins in WS such as mucins. There are a 
few explanations for the negative TG2 result in WS. Firstly, The TG2 antibody used in 
this study is raised against a 15 residue synthetic peptide derived from the C-terminu s of 
TG2, rather than the full length TG2 protein. Therefore, the antibody is more vulnerable 
to the loss of epitope through e.g. proteolytic fragmentation of TG in the oral cavity. It is 
• feasible that such degradation had occurred during WS samples processing, since protein 
degradation in WS has been shown to occur42.43. The use of "cocktail antibodie s" 
containing multiple monoclonal antibodies recognizing different TG2 domains can 
possibly be used in future immunoblotting experiments . 
At present, there is only one study published on detecting salivary TG 37• The authors 
demonstrated the co-existence of TG l , TG2, TG3 and TG4 in human saliva, with TG2 
and TG3 found in native and multiple proteolytic forms. The authors used pab0060, 
pab0062, mab0058, pab0066 antibodie s from Covalab (Villeurbanne , France) to detect 
the presence of TG 1, TG2 , TG3, and TG4 in saliva respectively . Their TG2 antibody 
targets a domain that is different from the C-terminal domain targeted by the Zedira 
antibody used in our study. The authors also showed that both TG l and TG2 were highly 
active with the major activity originating from TG 1, using a Transglutamina se 
Colorimetric Microas say kit (Covalab ). The kit uses CBZ-Gln-Gly as the glutamine 
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donor and biotinylated-cadaverine as the glutamine acceptor for TG. The absence of TG2 
(and TG3, TG5) protein detection in our WS samples seems to be discrepant with these 
published data. Given the richness of proteins in WS, there is a valid concern that any 
antibody used to detect specific proteins might cross-react with non-intended targets. This 
could have been the case in the published study, since multiple bands were observed with 
virtually all TG antibodies employed. On the other hand, the absence of mammalian TG 
protein seems inconsistent with the presence of EDT A-sensitive TG activity detected in 
WS. Therefore, further TG characterization in human WS is needed. 
5.2 TG activity in the human oral cavity 
Two different methods were used in determining TG activity in the human oral cavity. 
The method employed to determine TG activity in WS and dental plaque was the 
fluorescent casein-monodansylcadaverine assay. In that assay, TG catalyzes the covalent 
bonding of monodansylcadaverine and casein, which initiates a shift in intensity and 
wavelength of fluorescence of the dansyl group. By measuring the fluorescence signal, 
the transglutaminase activity can be monitored. The main advantage of this method is 
high sensitivity, although the results could be affected by interference of unreactive 
fluorescent molecules 44 . 
From the results obtained it can be concluded that WS displays TG activity that can be 
partly inhibited by EDTA (inhibitor of mammalian TG) but not by MTG inhibitor 
(putative inhibitor for microbial TG). Although the data shown are from one single 
reading and need replicates to be further interpreted, they suggested that MTG 
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contributed little to WS TG activity while calcium-dependent human TG was the main 
component of WS TG . activity. This is consistent with the fact that mammalian cells 
constitute the major cellular fraction of WS (by volume). The WS supernatant group 
presented with low TG activity, suggesting that TG activity mainly existed in the pellet 
fraction and that the contributing TGs were primarily cell-bound . Evidence for microbial 
TG activity was obtained with the dental plaque material. Further validation for the 
microbial origin of the activities observed in dental plaque is needed .. 
The demonstration that MTG-producing bacteria exist in the oral cavity prompted us to 
develop a method to directly screen oral bacteria. The S. mobaraensis-derived MTG was 
concentrated to be used as the positive control. To test its activity, the colorimetric 
hydroxamate assay was used, in which CBZ-Gln-Gly is the glutamine donor and 
hydroxylamine is the glutamine acceptor. In the presence of MTG, CBZ-Gln-Gly was 
crosslinked with hydroxylamine and developed a colored complex with iron. The main 
limitation of the hydroxamate method is the low sensitivity. The advantage though is that 
TG activities can be rapidly visualized45 and that the method can possibly be developed 
into a large scale agar-based screening assay for oral microbial colonies with 
transamination activties. S. mobaraensis colonies could serve as a positive control in such 
a screenmg. 
5.3. Data mining for oral microbial TG 
The S. mobaraensis TG was blasted against UniProt and HOMD databases. In UniProt, 
we limited the results within the category of bacteria and found 34 hits, among which 
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Streptomyces species are the only species that contained all three amino acids of the 
catalytic triad of MTG. Streptomyces, regarded as the largest genus of the Actinobacteria, 
are Gram-positive and commonly found in soil and decaying vegetation. 46 Another 
species, Saccharomonospora viridis, was ranked with 100% sequence homology and also 
contained all three MTG active sites. It is a Gram-negative bacterium that belongs to the 
family Pseudonocardiaceae and has been frequently found in hot compost and hay47 . 
None of the 34 bacterial hits is regarded as common habitant of oral cavity and none is 
listed in the oral taxon table at the HOMD. When the S. mobaraensis MTG sequence was 
blasted against the HOMD database, we found one match with Stenotrophomonas 
maltophilia, expressing three proteins with partial (low) similarity to S. mobaraensis TG. 
The fact that this species was not detected in the original Uniprot blast search could 
indicate that the sequence homology was too low and/or that the genome data of Uniprot 
were not yet updated with the genome data for this particular microorganism. 
Stenotrophomonas maltophilia frequently colonizes breathing tubes such as endotracheal 
or tracheo stomy tubes, the respiratory tract and indwelling urinary catheter s, rather than 
being a common colonizer of the oral cavity. Going forward, there are a few 
considerations to be taken into account. Firstly, common oral colonizers could express a 
TG that is unlike S. mobaraensis TG, which would explain why they were not picked up 
by blasting S. mobaraensis TG. Secondly , while the most common oral microbes have 
been sequenced , oral bacterial genome databases are continually being updated with 
newly sequenced species. Consequently, a match could have been missed, due to the 
unavailability of the genomic data. 
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Research on oral microbial TG is in its infancy. Our detection of TG activity in dental 
plaque warrants further investigation into the type of TG enzyme(s) , and bacterial 
source(s). Furthermore, activity assessment utilizing gluten instead of casein as the 
glutamine donor will be of interest to detect cross-linking activities relevant in CD. 
6. Conclusion 
CD is one of the most common autoimmune diseases and has serious complications in 
undiagnosed patients. A thorough characterization of TGs in the oral cavity will help us 
to determine if the deamidation of gliadins can already take place in the oral cavity, as 
opposed to being restricted to the small intestine as is commonly believed. It may revise 
our concept on the anatomical location where gluten "toxification " by TG takes place. 
The contribution of oral bacterial and/or mammalian TG to the pathogenesis of CD might 
be largely underestimated. The present studies lay the groundwork for a continued 
exploration into their physiological importance and therapeutic potential. 
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